SCHEMBL4415185

SCHEMBL4415185

Cc1cccc(Nc2ncnc3c2ccn3C(=O)O)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
KDM4E B2RXH2 2/20 0.58
EGFR P00533 8/20 0.54
PIP4K2A P48426 1/20 0.54
PIK3CG P48736 1/20 0.54
TP53 P04637 1/20 0.54
ALDH1A1 P00352 3/20 0.54
MAPT P10636 3/20 0.54
HTT P42858 1/20 0.53
HIF1A Q16665 1/20 0.53
ERBB2 P04626 4/20 0.51
MAPK1 P28482 1/20 0.51
MEN1 O00255 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7022803 0.90 KDM4E (0.58) LMNAKDM4EEGFRPIP4K2APIK3CG
Hydrochloric Acid SCHEMBL7026602 0.89 KDM4E (0.57) LMNAKDM4EEGFRPIP4K2APIK3CG
SCHEMBL4412294 0.86 PIP4K2A (0.69) LMNAKDM4EEGFRPIP4K2APIK3CG
SCHEMBL4427009 0.85 AURKA (0.58) KDM4EEGFR
SCHEMBL4421383 0.85 RAB9A (0.57) LMNAKDM4EEGFRPIP4K2APIK3CG
SCHEMBL4414264 0.85 MAPT (0.57) LMNAKDM4EEGFRTP53ALDH1A1
SCHEMBL4415661 0.85 EGFR (0.52) LMNAKDM4EEGFRPIP4K2APIK3CG
SCHEMBL4416404 0.85 ABCG2 (0.57) LMNAKDM4EEGFRPIP4K2APIK3CG
SCHEMBL4414170 0.84 ALDH1A1 (0.54) LMNAKDM4EPIP4K2APIK3CGALDH1A1
SCHEMBL4414043 0.84 PIP4K2A (0.48) LMNAKDM4EEGFRPIP4K2APIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658290-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-15 EP claimed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US claimed
JP-2007504159-A 2007-03-01 JP claimed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP claimed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO claimed
EP-1658290-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-15 EP disclosed
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-08 US disclosed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US disclosed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP disclosed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS LCK, FYN, BMX LMNA 3955/4885KDM4E 3165/4885EGFR 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.